Robert D. Bruno, Ph.D.
Publications
Bruno RD, Boulanger CA, Rosenfield SM, Anderson LH, Lydon JP, Smith GH. “Paracrine rescued lobulogenesis in chimeric outgrowths comprised of progesterone receptor null mammary epithelium and redirected wild-type testicular cells.” J Cell Sci. Epub Ahead of Print. 11/4/13.
Bruno RD, Rosenfield SM, Smith GH. “Late developing mammary tumors and hyperplasia induced by a low-oncogenic variant of mouse mammary tumor virus (MMTV) express genes identical to those induced by canonical MMTV.” Mol Cancer. 2013 Jul 18;12(1):79.
Boulanger CA*, Bruno RD,* Mack DL, Gonzales M, Castro NP, Salomon DS, Smith GH. “Embryonic stem cells are redirected to non-tumorigenic epithelial cell fate by interaction with the mammary microenvironment.” PLoS One. 2013 Apr 26;8(4) *equal contributing first authors.
Bruno RD, Smith GH. “Reprogramming non-mammary and cancer cells in the developing mouse mammary gland.” Semin Cell Dev Biol. 2012 Jul;32(5):591-8.
Bruno RD, Smith GH. “Role of epithelial stem/progenitor cells in mammary cancer.” Gene Expr. 2011;15(3):133-40.
Bruno RD, Boulanger CA, Smith GH. “Notch-induced mammary tumorigenesis does not involve the lobule-limited epithelial progenitor.” Oncogene. 2012 Jan 5;31(1):60-7
Bruno RD, Vasaitis TS, Gediya LK, Puruschottamachar P, Godbole AM, AtesAlagoz Z, Brodie AM, Njar VC. “Synthesis and biological evaluations of putative metabolically stable analogs of VN/124-1 (TOK-001): head to head anti-tumor efficacy evaluation of VN/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model.” Steroids. 2011 Nov; 76(12): 1268-79
Boulanger CA, Bruno RD, Rosu-Myles M, Smith GH. “The Mouse Mammary Microenvironment Redirects Mesoderm-Derived Bone Marrow Cells to a Mammary Epithelial Progenitor Cell Fate.” Stem Cells Dev. 2011 Jul 18 [Epub ahead of print].
Vasaitis TS, Bruno RD, Njar VC. “CYP17 inhibitors for prostate cancer therapy.” J Steroid Biochem Mol Biol. 2011 May; 125(1-2):23-31.
Bruno RD, Smith GH, “Functional Characterization of Stem Cell Activity in the Mouse Mammary Gland.” Stem Cell Rev. 2011 Jun;7(2):238-47.
Bussard KM, Boulanger CA, Booth BW, Bruno RD, Smith GH. “Reprogramming human cancer cells in the mouse mammary gland.” Cancer Res. 2010 Aug 1;70(15):6336-43.
Bruno RD, Gover, TD, Burger AM, Brodie, AM, Njar VC. “17a-Hydroxylase/17,20 lyase inhibitor VN/124-1 inhibits growth of androgen-independent prostate cancer cells via induction of the endoplasmic reticulum stress response.” Mol Cancer Ther. 2008; Sep;7(9):2828-36
Purushottamachar P, Khandelwal A, Vasaitis TS, Bruno RD, Gediya, LK, Njar VC. “Potent anti-prostate cancer agents derived from a novel androgen receptor down-regulating agent.” Bioorg Med Chem. 2008 Apr 1;16(7):3519-29
Bruno, RD, Njar VCO. “Targeting cytochrome P450 enzymes: A new approach in anti-cancer drug development”. Bioorg. Med. Chem. 2007 Aug 1;15(15):5047-60.
Purushottamachar P, Khandelwal A, Chopra P, Maheshwari N, Gediya LK, Vasaitis TS, Bruno RD, Clement OO, Njar VC. “First pharmacophore-based identification of androgen receptor down-regulating agents: Discovery of potent anti-prostate cancer agents.” Bioorg Med Chem. 2007 May 15;15(10):3413-21.